Theregen - Company Information on Theregen

Press Enter or Click Search to perform a full site search.

Company Name Matches

Show All Search Results »

Companies>Theregen

Add to Watch List Share This Page

Email Page Flag This Page

Flag

Headline: Regenerate medicine solutions

Website: http://www.theregencompany.com/

Theregen's product development program for Anginera is based on Dermagraft, an FDA-approved, cell-based wound management product. The Anginera technology platform applies a solid foundation of proven research into the cardiovascular arena. Backed by compelling animal data in several heart models, Theregen scientists are preparing to advance into clinical studies in the human heart.

Address: 225 Bush St. 16th Floor San Francisco, CA 94105 Map it »

Phone: 415-439-8320

Email: info@theregen.com

Industry: Biopharmaceuticals

Sub-Industry: Drug Development Technologies

Legal Structure: Corporation

Ownership: Private

Tags:

Add a tag

Management

Board of Directors

Timothy Mills [x]

Date	Type	Capital Amount	Post-Money Valuation	Investors
01/18/2006	Series A	1.5M	Unknown	Sanderling, Guidant

Name:	Anginera™
Product URL:	http://www.theregencompany.com/products.html
Description:	Theregen's primary corporate objective is the clinical development and approval of Anginera. Anginera initially will treat diffuse small vessel disease associated with myocardial ischemia and will serve as an adjunct to revascularization procedures that include coronary arterial bypass graft (CABG) surgery and percutaneous coronary angioplasty with stenting. Anginera also may have the potential to treat patients with reversible ischemia associated with chronic heart failure, a much larger market than diffuse small vessel disease. Anginera is an epicardial cell-based therapy similar to Dermagraft™, an FDA-approved wound management product. This heart therapy may require two or more Anginera patches applied directly to the surface of the heart (epicardium) during conventional bypass surgery. Preclinical studies suggest that Anginera promotes angiogenesis and arteriogenesis (small blood vessel development) when placed onto the surface of a damaged heart. Anginera's technology platform uses human fibroblast cells cultured and grown on a three-dimensional bioabsorbable scaffold material to create a viable tissue. When applied as an epicardial patch to an ischemic area of the heart, the living tissue provides a source of the cytokines and growth factors needed to induce angiogenesis and tissue repair. The preclinical studies have also provided evidence that Anginera supports improved function in a chronic ischemic heart model. A major benefit of Anginera treatment may be the improvement of blood flow to areas of the heart that are not treatable by conventional revascularization therapies (e.g., CABG and stents).